I see a lot of discussion elsewhere regarding rumors of a buy-out or a single large partner. The company clearly defines its strategic plans.
About Actinium Pharmaceuticals
“Company intends to develop its products through Phase II clinical trials and it then intends to partner each drug for completion of development and commercialization with an appropriate third party. ATNM expects that its revenues will be derived from upfront payments, milestone payments and royalty payments, which payments comprise a standard structure of such partnering deals. In some markets, ATNM may seek to retain commercial rights and derive additional revenue from sales of its products.”
Intellectual Property
“ATNM is continuously working on enhancing its IP portfolio, including notably initiatives to strengthen its intellectual property related to cyclotron based production of Ac-225.” Reference NBC news piece about Los Alamos.
Platform Strategy
“With our APIT platform, we can create second generation drugs with superior efficacy for marketed mAb drugs. As patent protection for many native mAbs approaches expiration, we will be able to offer the owners of those mAbs our technology that will create new, better drugs and give them new patent protection. We intend to form valuable alliances, joint ventures and/or licensing deals with companies having commercial mAb drugs. We expect this strategy to result in additional growth potential for the company.”
Products, Pipeline, Preclinical
“Colorectal cancer, metastatic: ATNM has been working collaboratively with the owner of rights to an anti-A33 mAb that targets metastatic colon cancer, to co-develop that mAb labeled with Ac-225.”
“Prostate cancer, metastatic: ATNM has also collaborated with MSKCC and a commercial third party on development of an Ac-225 labeled mAb highly specific for prostate cells.” “ATNM has had discussion with the antibody owner and is currently evaluating approaches for a collaboration proposal to the owner of antibody rights.”
“Due to availability of extensive clinical data on the use of the above listed mAbs both as native and as radiolabeled, and extensive clinical data on the use of our anti-leukemia mAb (HuM195 labeled with either Bi-213 and Ac-225), ATNM expects to pursue a regulatory clearance of a Physician trial IND from the FDA which would allow a Company sponsored Phase I trial to begin within 8 – 12 months in one of the above indications once funding is provided and a final agreement has been reached with the antibody owners.
In earlier stages of preclinical work, MSKCC has been developing another antiangiogenesis mAb coupled with Ac-225. This construct could potentially be useful for treating most if not all metastatic solid cancers and has shown an excellent safety and efficacy profile in vivo in mouse models. The mAb rights are owned by a third party and ATNM intends to commence discussions with that party to explore opportunities for cooperation once further feasibility studies at MSKCC are completed.”
Letter to Shareholders November 2015
A Promising Outlook in 2016
“Actinium’s strategy is to progress Iomab-B and Actimab-A through their clinical trials, obtain regulatory approval and launch these therapies commercially either alone or with partners. Strategic licensing is very much a core element of our strategy. We find our recent developments to be very exciting, based on positive clinical results for Actimab-A and overcoming past technical challenges of Iomab-B. We look forward to delivering on our major objectives for 2016, which are:
Actively explore strategic licensing and collaborations as appropriate plan for 2016 and beyond”
“We intend to ramp up our efforts to form strategic alliances with potential partners to extend our product development efforts and our geographic reach in key markets outside the United States.”
The company’s strategic plan as laid out above indicates a longer term plan. Monday’s attendance at the Biotech Showcase is in furtherance of their strategic plan.
http://www.ebdgroup.com/bts/media/about_conf.php
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and potential strategics in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.
If you're looking for whales you might miss the school of fish feeding right in front of you.
Once sales and licensing fees and royalties prove themselves, then watch for the whale.
News 
Market Data 
Discover 
AI
